African Genetic Diversity

Preparation

Comparisons

Evidence quality

Where it comes from

Highlighted claims

• Current pharmacogenetic and pharmacokinetic evidence is heavily biased toward European and Asian populations. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• African populations have high genetic diversity, distinct haplotypes and a greater likelihood of novel variants compared to European and Asian populations. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• The whole genome sequencing subset will be selected to maximise genetic diversity and capture KhoeSan, Damara, Ovambo, Tswana and Herero ancestry. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• The Khoe-San population is recognised as one of the most genetically diverse populations globally and may carry population-specific variants relevant to TB drug response. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• Genotype imputation using the African Genome Resource has been shown to be the best reference panel for admixed South African populations. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort